Korro Bio, Inc. (KRRO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.24+5.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KRRO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 15.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -84.9% |
Growth built into the price is above our model estimate.
The price assumes 100.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KRRO — litigation filed
Dated 2026-08-19
Other Events. On August 19, 2026, Korro Bio, Inc., or Korro, announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide in development for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders, or UCDs. The purpose of the Phase 1/2 clinical trial for KRRO-121 is to determine the safety and tolerability of escalating doses, evaluate it…
Why it matters: Updates on changes show how well the company controls costs.
Supportive ifManagement shares a goal to cut costs. They also share a schedule for changes.
Worry ifNo news or delays about changes are shared.
Why it matters: Nominating a third program could grow Korro's pipeline and support its OPERA platform. This would show potential for growth.
Supportive ifKorro will announce a third GalNAc-conjugated program in the second half of 2026.
Worry ifNo announcement is made regarding the third program by the end of 2026.
Why it matters: Extending the cash runway is crucial for Korro Bio's survival and growth plans.
Supportive ifManagement shares news about a financing deal or cost-saving steps. This helps extend cash runway.
Worry ifThere is no progress on cash runway. This may lead to funding problems.
Why it matters: Positive data could show KRRO-111's promise as a treatment for AATD. It may improve how the market views it.
Supportive ifKorro presents positive preclinical data for KRRO-111 at the ASGCT meeting in May 2026.
Worry ifData presented at ASGCT shows poor results for KRRO-111.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$312 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $822 loss on $10,000 · 8.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,972 loss on $10,000 · 89.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This filing is key for starting clinical trials. It shows progress in treating hyperammonemia.
Supportive ifManagement plans to file for KRRO-121 with regulators in the second half of 2026.
Worry ifIf no filing is made by the end of 2026, it shows delays in development.
Why it matters: Updates will show how the company is handling costs and cash.
Supportive ifManagement talks about plans to save money. They also share good news about changes.
Worry ifNo news or bad news about the changes.
Why it matters: Restructuring can help Korro Bio cut costs and be more financially stable.
Supportive ifManagement talks about successful cost cuts. They also share good results from restructuring.
Worry ifNo news on restructuring means high costs and financial stress continue.
Why it matters: Following the recent earnings beat, Q2 results will indicate if the trend continues.
Supportive ifQ2 earnings report shows revenue growth or improved margins compared to Q1.
Worry ifQ2 earnings report shows revenue decline or margins worsen compared to Q1.
Why it matters: Announcing this candidate shows progress in Korro's work. It could help investors feel more confident.
Supportive ifKorro will announce a development candidate for the GalNAc AATD program in Q2 2026.
Worry ifNo news will come about the development candidate in Q2 2026.
Why it matters: If sector growth improves, it could benefit Korro Bio. A stronger sector can lift all companies within it.
Supportive ifHealth Care sector revenue growth is speeding up again. This shows a good trend.
Worry ifSector revenue growth keeps slowing down. This shows ongoing weakness.
Why it matters: Approval is crucial for starting clinical trials for KRRO-121, a key product. It could validate Korro's RNA editing platform.
Supportive ifKRRO-121 got regulatory approval to start clinical trials in late 2026.
Worry ifRegulatory approval is delayed or denied. This stops the clinical trial process.
Why it matters: Positive data could strengthen the case for KRRO-111 as a best-in-class treatment for AATD. It may enhance investor confidence.
Supportive ifClinical data shows over 90% RNA editing success for KRRO-111 at a conference.
Worry ifNo important clinical data is shown or data shows less success than expected.
Why it matters: Updates on cash will show financial health and ability to fund projects. This affects investors.
Watch forCash and securities total over $137.9 million. This funds operations until 2028.
Also watch forCash is below $100 million, which may cause funding problems.